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*Bordetella pertussis* causes whooping cough, a contagious respiratory disease that has been resurging recently despite high vaccination coverage.[^1^](#mim12791-bib-0001){ref-type="ref"}, [^2^](#mim12791-bib-0002){ref-type="ref"} This organism produces multiple virulence factors, including toxins and adhesins, the expression of which is largely regulated by the BvgAS two‐component system, consisting of the sensor kinase BvgS and response regulator BvgA.[^3^](#mim12791-bib-0003){ref-type="ref"} At 37°C in standard *Bordetella* media, the BvgAS system activates the transcription of a set of genes (Bvg‐activated genes) including various virulence genes. Conversely, this system is inactivated at temperatures lower than 26°C or in the presence of MgSO~4~ (40--50 m[m]{.smallcaps}) or nicotinic acid (10--20 m[m]{.smallcaps}), and *B. pertussis* eventually does not express the Bvg‐activated genes. The former bacterial state is called the Bvg^+^ phase, and the latter is the Bvg^−^ phase. The BvgAS system is considered to play a major role in the expression of genes involved in the pathogenesis of *B. pertussis*; however, recent *in vivo* studies found that several Bvg‐activated genes were repressed in *B. pertussis* colonizing the respiratory tracts of mice.[^4^](#mim12791-bib-0004){ref-type="ref"}, [^5^](#mim12791-bib-0005){ref-type="ref"} van Beek *et al*. also reported that approximately 30% of all genes were differentially expressed between *in vitro* and *in vivo* conditions.[^4^](#mim12791-bib-0004){ref-type="ref"} Furthermore, a *B. pertussis* clinical strain, the BvgAS system of which was dysfunctional due to a spontaneous mutation in the *bvgS* gene, was isolated from a pertussis patient.[^6^](#mim12791-bib-0006){ref-type="ref"} These findings suggest that a complex mechanism, besides the BvgAS system, is involved in the regulation of the bacterial gene expression during the course of infection.

Bacterial small RNAs (sRNAs) are functional noncoding RNA molecules that range between 50 and 500 nucleotides in length.[^7^](#mim12791-bib-0007){ref-type="ref"} Previous studies identified numerous sRNAs in various pathogenic and commensal bacteria using a computational analysis and laboratory‐based techniques, such as microarrays, Northern blotting, and RNA sequencing (RNA‐seq).[^8^](#mim12791-bib-0008){ref-type="ref"}, [^9^](#mim12791-bib-0009){ref-type="ref"}, [^10^](#mim12791-bib-0010){ref-type="ref"}, [^11^](#mim12791-bib-0011){ref-type="ref"} Most sRNAs post‐transcriptionally upregulate or downregulate downstream gene expression by affecting the stability and translational efficiency of target messenger RNAs (mRNAs) through base pairing with them.[^12^](#mim12791-bib-0012){ref-type="ref"}, [^13^](#mim12791-bib-0013){ref-type="ref"} A wide variety of physiological processes, including metabolism, stress responses, and the expression of virulence genes, are regulated by sRNAs.[^14^](#mim12791-bib-0014){ref-type="ref"}, [^15^](#mim12791-bib-0015){ref-type="ref"}, [^16^](#mim12791-bib-0016){ref-type="ref"}, [^17^](#mim12791-bib-0017){ref-type="ref"}, [^18^](#mim12791-bib-0018){ref-type="ref"} In *B. pertussis*, many types of sRNAs have been identified or predicted by an *in silico* analysis and RNA‐seq on the bacteria grown *in vitro*.[^9^](#mim12791-bib-0009){ref-type="ref"}, [^11^](#mim12791-bib-0011){ref-type="ref"}, [^14^](#mim12791-bib-0014){ref-type="ref"} However, it currently remains unclear whether *B. pertussis* sRNAs are involved in the regulation of *in vivo* gene expression, which is associated with the establishment of bacterial infection. In the present study, we performed *in vivo* RNA‐seq on *B. pertussis* colonizing the murine tracheas and identified novel sRNAs that were strongly expressed during colonization.

*In vivo* expression of sRNAs were analyzed by RNA‐seq using tracheas of three mice independently infected with *B. pertussis*‐type strain 18323. This organism was grown at 37°C on Bordet--Gengou agar (Becton Dickinson, Franklin Lakes, NJ) containing 1% HIPOLYPEPTON (Nihon Pharmaceutical, Tokyo, Japan), 1% glycerol, 15% defibrinated horse blood, and 10 µg/mL ceftibuten (BG plate). The bacteria recovered from the colonies on BG plates were suspended in Stainer--Scholte (SS) broth[^19^](#mim12791-bib-0019){ref-type="ref"} to obtain an OD~650~ of 0.2, and cultured at 37°C for 14 hr with shaking. Bacterial CFUs were estimated from OD~650~ values according to the following equation: 1 OD~650~ = 3.3 × 10^9^ CFU/mL. Seven‐week‐old male C57BL/6J mice (CLEA Japan, Osaka, Japan) were anesthetized with a mixture of medetomidine (Kyoritsu Seiyaku, Tokyo, Japan), midazolam (Teva Takeda Pharma, Nagoya, Japan), and butorphanol (Meiji Seika Pharma, Yokohama, Japan) at final doses of 0.3, 2, and 5 mg/kg body weight, respectively, and intranasally inoculated with *B. pertussis* 18323 (1 × 10^7^ CFU) in 50 μL of SS medium using a micropipette with a needle‐like tip. On Day 4 after inoculation, mice were killed with pentobarbital, and the tracheas were excised and frozen in liquid nitrogen. Total RNA was extracted from the tracheas with TRIzol Reagent (Thermo Fisher Scientific, Waltham, MA), treated with RNase‐Free DNase (Takara Bio, Shiga, Japan), and then purified with the PureLink RNA Mini Kit (Thermo Fisher Scientific) according to the manufacturer\'s instructions. Bacterial and murine ribosomal RNAs (rRNAs) were simultaneously depleted from the total RNA using the Ribo‐Zero rRNA Removal Kit for Human/Mouse/Rat and Gram‐Negative Bacteria (Illumina, San Diego, CA). The quality and quantity of RNA samples were assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Reverse transcription was performed with the rRNA‐depleted RNA, SuperScript III Reverse Transcriptase (Thermo Fisher Scientific), and Random Primer N9 (Takara Bio), and double‐stranded DNA was then synthesized using DNA polymerase I (Klenow fragment \[3′--5′ exo‐\]; New England Biolabs, Ipswich, MA). The resultant complementary DNA (cDNA) was sheared to approximately 600 bp fragments using Covaris S220 (Covaris, Woburn, MA) and purified with Agencourt AMPure XP beads (Beckman Coulter, Miami, FL). Libraries of the cDNA fragments were then prepared with the KAPA Library Preparation Kit (Kapa Biosystems, Wilmington, MA) and TruSeq adapters (Illumina), and sequenced with a HiSeq 2500 (Illumina) to obtain 101 bp single‐end reads. The sequenced reads were mapped to the genomic DNA of *B. pertussis* 18323 (GenBank: NC_018518.1) using CLC Genomics Workbench, version 8.0.3 (CLC bio, Waltham, MA). All animal experiments were approved by the Animal Care and Use Committee of the Research Institute for Microbial Disease, Osaka University, and conducted according to the Regulations on Animal Experiments at Osaka University. The numbers of total sequenced reads were 54, 143, and 137 million, and 0.06%, 0.72%, and 0.04% of the reads in each sample were aligned to the genome sequence of *B. pertussis* 18323. A large portion of the reads aligned to the bacterial genome corresponded to protein‐, rRNA‐, and transfer RNA‐coding sequences (95.5%, 99.9%, and 97.3%), whereas the residual reads were aligned to the intergenic regions: the numbers of reads were 1180, 1316, and 836, respectively. We predicted that these noncoding sequences located in the intergenic regions are potential sRNA sequences. Among these sRNA candidates, we selected nine novel sRNAs, for which the number of sequenced reads was more than 20 counts, and designated them *B. pertussis* sRNA (Bpr)1--9 according to a previous study[^9^](#mim12791-bib-0009){ref-type="ref"} (Table [1](#mim12791-tbl-0001){ref-type="table"}). Homologous sRNAs to Bpr1--9 were not found in the public databases including BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) and sRNAMap (<http://srnamap.mbc.nctu.edu.tw>).

###### 

Genetic localization of Bpr in *Bordetella pertussis* 18323

  sRNA                                                 Coordinate[^a^](#mim12791-tbl1-note-0001){ref-type="fn"}   Predicted sRNA size (base)   IGR length[^b^](#mim12791-tbl1-note-0002){ref-type="fn"}   Adjacent genes   Number of reads[^c^](#mim12791-tbl1-note-0003){ref-type="fn"}                     
  ---------------------------------------------------- ---------------------------------------------------------- ---------------------------- ---------------------------------------------------------- ---------------- --------------------------------------------------------------- ----- ----- ----- -----
  Bpr1[^d^](#mim12791-tbl1-note-0004){ref-type="fn"}   615294                                                     615326                       33                                                         253              *bn118_rs02945*/*purM*                                          536   369   485   463
  Bpr2[^d^](#mim12791-tbl1-note-0004){ref-type="fn"}   615326                                                     615294                       33                                                         253              *bn118_rs02945*/*purM*                                          93    57    125   92
  Bpr3                                                 3280265                                                    3280530                      266                                                        893              *rplN*/*gabD*                                                   157   30    62    83
  Bpr4                                                 971049                                                     971071                       23                                                         231              *bn118_rs04605*/*IS481*                                         69    26    92    62
  Bpr5                                                 3280631                                                    3280424                      208                                                        893              *rplN*/*gabD*                                                   113   22    9     48
  Bpr6                                                 1174521                                                    1174937                      417                                                        727              *map*/*rpsB*                                                    87    19    33    46
  Bpr7                                                 1175217                                                    1174967                      251                                                        727              *map*/*rpsB*                                                    76    21    8     35
  Bpr8                                                 410106                                                     409944                       163                                                        595              *sphB1*/*ppc*                                                   77    19    9     35
  Bpr9                                                 1432753                                                    1432869                      117                                                        308              *bn118_rs06780*/*rplS*                                          43    18    8     23
  *recA*                                               2148903                                                    2147842                      1062                                                       --               *recX*/*ompR*                                                   30    46    45    40

Coordinate in the *B. pertussis* 18323 genome sequence (NC_018518.1).

Length of the IGR containing sRNA coding genes.

The number of sequenced reads corresponding to each Bpr obtained by *in vivo* RNA‐seq using three murine tracheas colonizing *B. pertussis*.

Bpr1 and Bpr2 carry complementary sequences to each other.

John Wiley & Sons, Ltd.

*In vitro* and *in vivo* expression of Bpr1--9 were compared by qRT‐PCR analyses. Total RNA was extracted and purified from the tracheas of mice independently infected with *B. pertussis* Tohama, a vaccine strain, and two clinical strains (BP139 and BP143 gifted from K. Kamachi, National Institute for Infectious Diseases)[^20^](#mim12791-bib-0020){ref-type="ref"} in the same manner as *B. pertussis* 18323. Total RNA was also prepared from the four strains of *B. pertussis* and Bvg^+^‐ and Bvg^−^‐locked mutants derived from *B. pertussis* 18323 grown *in vitro* using the PureLink RNA Mini Kit and RNase‐Free DNase according to the manufacturer\'s instructions. The Bvg^+^‐ and Bvg^−^‐locked mutants, which constitutively express the Bvg^+^ and Bvg^−^ phenotypes, respectively, were constructed by the site‐directed mutagenesis of BvgS to replace Arg with His at position 570 and to delete the region of amino acid positions from 542 to 1020, respectively,[^21^](#mim12791-bib-0021){ref-type="ref"} using double‐crossover homologous recombination as described previously.[^22^](#mim12791-bib-0022){ref-type="ref"} In brief, the plasmids *bvgS*‐C3‐pABB‐CRS2‐Gm and Δ*bvg*S‐pABB‐CRS2‐Gm[^22^](#mim12791-bib-0022){ref-type="ref"} were introduced into *Escherichia coli* DH5α λ*pir*, and then transconjugated into *B. pertussis* 18323 by triparental conjugation with the helper strain *E. coli* HB101 harboring pRK2013,[^23^](#mim12791-bib-0023){ref-type="ref"} which was provided by K. Minamisawa (Tohoku University). Total RNA samples (1 µg) from bacteria recovered from murine tracheas and *in vitro*‐cultured bacteria were reverse transcribed into cDNA using the PrimeScript RT Reagent Kit (Takara Bio) with random hexamers in a total volume of 20 µL. The transcription levels of target RNAs were estimated from the amounts of the resultant cDNA measured with the StepOnePlus Real‐Time PCR System (Applied Biosystems, Foster, CA) using the Power SYBR Green PCR Master Mix (Thermo Fisher Scientific) and the primers listed in Table [2](#mim12791-tbl-0002){ref-type="table"} under the following conditions: initial denaturation at 95°C for 10 min, and 40 cycles at 95°C for 15 s and 60°C for 1 min. qRT‐PCR analyses revealed that the expression levels of Bpr4, 5, 8, and 9 in *B. pertussis* 18323 colonizing murine tracheas were significantly higher (118‐, 64‐, 9‐, and 6‐fold, respectively) than those in *in vitro*‐cultured bacteria (Figure [1a](#mim12791-fig-0001){ref-type="fig"}). By contrast, no significant differences in the expression of Bpr1--3, 6, or 7 were observed between *in vitro* and *in vivo* conditions. Similar results were obtained with *B. pertussis* Tohama and two clinical strains (Figure [1b](#mim12791-fig-0001){ref-type="fig"}). The *in vitro* expression levels of Bpr1--7 and 9 in *B. pertussis* 18323 were largely unaffected by the absence or presence of 40 m[m]{.smallcaps} MgSO~4~. In addition, the Bvg^+^‐ and Bvg^−^‐locked mutants equally expressed these sRNAs (Figure [1c](#mim12791-fig-0001){ref-type="fig"}). By contrast, the expression of Bpr8 was negligible in *B. pertussis* 18323 wild‐type grown in the presence of 40 m[m]{.smallcaps} MgSO~4~ (i.e. Bvg^−^ phase condition) and the Bvg^−^‐locked mutant. These results indicate that the expression of Bpr1--7 and 9 is independent of the BvgAS regulatory system, whereas that of Bpr8 is BvgAS dependent.

###### 

Primers used in the present study

  Primers                                                    Sequence (5′--3′)                        Application
  ---------------------------------------------------------- ---------------------------------------- ---------------------------
  Bpr1, 2‐Fw[^a^](#mim12791-tbl2-note-0001){ref-type="fn"}   ACCCTGCATTAAACCACTGC                     qRT‐PCR for Bpr1 and Bpr2
  Bpr1, 2‐Rv[^a^](#mim12791-tbl2-note-0001){ref-type="fn"}   GCAAACCCCTGGAAATGCTC                     
  Bpr3‐Fw                                                    AACTGAAAACACGCCCTTCC                     qRT‐PCR for Bpr3
  Bpr3‐Rv                                                    ATTTCAACCCAGGGTCGTTC                     
  Bpr4‐Fw                                                    ATCGGCCGCGCAATCCGCTTG                    qRT‐PCR for Bpr4
  Bpr4‐Rv                                                    CCGGGCCCGCTATTTATTCAC                    
  Bpr5‐Fw                                                    CCGGTTTTGGTTGGACTTTC                     qRT‐PCR for Bpr5
  Bpr5‐Rv                                                    CCCGAAGGCTCATTCCAC                       
  Bpr6‐Fw                                                    AGGCAGGCAAGTAGCAAAGC                     qRT‐PCR for Bpr6
  Bpr6‐Rv                                                    CACAAATCGCCCAAAACACC                     
  Bpr7‐Fw                                                    CAGCATTTCACGCATGAGG                      qRT‐PCR for Bpr7
  Bpr7‐Rv                                                    TTTATCCGATGCGGGTGTAG                     
  Bpr8‐Fw                                                    TGCGTCCCAGGATGATTTG                      qRT‐PCR for Bpr8
  Bpr8‐Rv                                                    GTGCGAGGAGTGCGTTGAG                      
  Bpr9‐Fw                                                    TTGATGTAGAATGCTGGGTTTGC                  qRT‐PCR for Bpr9
  Bpr9‐Rv                                                    AACCAGGCAACGGCTATTGG                     
  recA‐Fw                                                    CCAATGTGGTCGACAAGTCC                     qRT‐PCR for *recA*
  recA‐Rv                                                    ATGGCCATTTCCTTGTGCTC                     
  Bpr4_RACE‐S                                                GATTACGCCAAGCTTATCGGCCGCGCAATCCGCTTG     RACE for Bpr4
  Bpr4_RACE‐AS                                               GATTACGCCAAGCTTCCGGGCCCGCTATTTATTCAC     
  Bpr5_RACE‐S                                                GATTACGCCAAGCTTCCGGTTTTGGTTGGACTTTC      RACE for Bpr5
  Bpr5_RACE‐AS                                               GATTACGCCAAGCTTCCCGAAGGCTCATTCCAC        
  Bpr8_RACE‐S                                                GATTACGCCAAGCTTTGCGTCCCAGGATGATTTG       RACE for Bpr8
  Bpr8_RACE‐AS                                               GATTACGCCAAGCTTGTGCGAGGAGTGCGTTGAG       
  Bpr9_RACE‐S                                                GATTACGCCAAGCTTTTGATGTAGAATGCTGGGTTTGC   RACE for Bpr9
  Bpr9_RACE‐AS                                               GATTACGCCAAGCTTAACCAGGCAACGGCTATTGG      
  Bpr4‐*Eco*RI‐S                                             AGGGAGACCGGAATTCCCGGGCCCGCTATTTATT       RNA probe for Bpr4
  Bpr4‐*Bam*HI‐AS                                            CGACTCTAGAGGATCCATCGGCCGCGCAATCCGC       
  Bpr5‐*Eco*RI‐S                                             AGGGAGACCGGAATTCCCCGAAGGCTCATTCCAC       RNA probe for Bpr5
  Bpr5‐*Bam*HI‐AS                                            CGACTCTAGAGGATCCCCGGTTTTGGTTGGACTTT      
  Bpr8‐*Eco*RI‐S                                             AGGGAGACCGGAATTCGTGCGAGGAGTGCGTTGA       RNA probe for Bpr8
  Bpr8‐*Bam*HI‐AS                                            CGACTCTAGAGGATCCTGCGTCCCAGGATGATTTG      
  Bpr9‐*Eco*RI‐S                                             AGGGAGACCGGAATTCAACCAGGCAACGGCTATTG      RNA probe for Bpr9
  Bpr9‐*Bam*HI‐AS                                            CGACTCTAGAGGATCCTTGATGTAGAATGCTGGGTT     
  recA‐*Eco*RI‐S                                             AGGGAGACCGGAATTCATGGCCATTTCCTTGTGCT      RNA probe for *recA*
  recA‐*Bam*HI‐AS                                            CGACTCTAGAGGATCCCCAATGTGGTCGACAAGTC      

Bpr1 and Bpr2 are amplified with Bpr1, 2‐Fw and Bpr1, 2‐Rv, respectively.

John Wiley & Sons, Ltd.

![*In vivo* and *in vitro* expression of *Bordetella pertussis* sRNAs. (a‐b) Mice were intranasally inoculated with *B. pertussis* 18323 (a and b), Tohama, BP139, or BP143 (b). Total RNA was extracted from the bacteria recovered from murine tracheas (*in vivo*) and *in vitro*‐cultured bacteria (*in vitro*) (a and b) or *B. pertussis* 18323 WT and Bvg^+^‐ and Bvg^−^‐locked mutants cultured in SS broth with or without 40 m[m]{.smallcaps} MgSO~4~ (c). The relative amount of each Bpr was assessed by qRT‐PCR with the ΔΔ*C* ~t~ method normalized to that of *recA* mRNA as an internal control for each sample. Data are represented as fold changes in expression from that observed in *in vitro*‐cultured bacteria (a and b) or WT grown in the absence of MgSO~4~ (c). Values are means and SEM (*n* = 3). Statistical analyses were performed by a two‐way analysis of variance and Tukey\'s multicomparison test using Prism 8 (GraphPad Software). \**P* \< 0.05, \*\**P* \< 0.01. mRNA, messenger RNA](MIM-64-469-g001){#mim12791-fig-0001}

The presence of Bpr4, 5, 8, and 9 in *B. pertussis* 18323 was confirmed by rapid amplification of cDNA end (RACE) and Northern blotting. For the determination of the transcription start and termination sites of the Bpr, 5′‐ and 3′‐RACE were performed using a SMARTer RACE 5′/3′ Kit (Takara Bio) according to the manufacturer\'s instructions. In brief, total RNA was extracted from *in vitro*‐cultured *B. pertussis* 18323 and polyadenylated by poly(A) polymerase (New England Biolabs). After reverse transcription by SMARTScribe Reverse Transcriptase, the resultant cDNA was used as a template for PCR with Universal primer and each *bpr*‐specific primers (Table [2](#mim12791-tbl-0002){ref-type="table"}). The PCR products were then cloned into linearized pRACE and five individual clones were sequenced. The precise transcription start and termination sites of Bpr4, 8, and 9 were poisoned at 971000--971155 (156 base), 410138--409796 (343 base), and 1432692--1433084 (393 base), respectively, in the *B. pertussis* 18323 genome sequence. By contrast, two start sites (3280825 and 3280639) and one termination site (3280298) were detected in the transcripts of Bpr5 (528 and 342 bases), indicating the presence of two overlapping transcripts of different length. Northern blotting was performed using a DIG Northern Starter Kit (Sigma‐Aldrich, St Louis, MO). For production of digoxigenin (DIG)‐labeled RNA probes, partial antisense strands of *bpr* and *recA* genes were amplified from *B. pertussis* 18323 using appropriate primers (Table [2](#mim12791-tbl-0002){ref-type="table"}), and cloned into the downstream of T7 promoter on pSPT18 (Sigma‐Aldrich). The resulting plasmids were linearized with *Sal*I, and DIG‐labeled RNA probes were generated by *in vitro* transcription with T7 polymerase. Next, total RNA (20 μg) extracted from *in vitro*‐cultured *B. pertussis* 18323 was subjected to electrophoresis in a 1.5% denaturing formaldehyde agarose gel, transferred to a positively charged membrane (Hybond‐N+; GE Healthcare, Piscataway, NJ), and UV cross‐linked to the membrane. The membrane was then independently incubated with DIG‐labeled RNA probes for each Bpr and *recA*, respectively, followed by alkaline phosphate‐conjugated sheep anti‐DIG immunoglobulin G, and visualized with CDP‐*Star*. Northern blotting using the RNA probes for Bpr4, 8, and 9 detected a single band, whereas Bpr5 migrated as two bands (Figure [2](#mim12791-fig-0002){ref-type="fig"}). The mobility of each Bpr corresponded to that estimated from its length determined by RACE.

![Experimental validation of the sRNAs expression in *Bordetella pertussis*. Total RNA extracted from *in vitro*‐cultured *B. pertussis* 18323 was subjected to Northern blotting using RNA probes for the detection of Bpr4, 5, 8, and 9, and *recA*](MIM-64-469-g002){#mim12791-fig-0002}

sRNAs regulate the expression of genes involved in a wide variety of physiological processes in bacteria, including the adaptation to host environments and virulence.[^14^](#mim12791-bib-0014){ref-type="ref"}, [^15^](#mim12791-bib-0015){ref-type="ref"}, [^16^](#mim12791-bib-0016){ref-type="ref"}, [^17^](#mim12791-bib-0017){ref-type="ref"}, [^18^](#mim12791-bib-0018){ref-type="ref"} In *B. pertussis*, 14 types of sRNAs designated as BprA--N were identified by an *in silico* analysis and Northern blotting[^9^](#mim12791-bib-0009){ref-type="ref"}; however, these sRNAs have not yet been characterized. Recent studies performed an RNA‐seq analysis using *B. pertussis* grown *in vitro* and identified an sRNA designated as RgtA ([r]{.ul}epressor of [g]{.ul}lutamate [t]{.ul}ransport) that was found to reduce the translation of BP3831, a periplasmic amino acid‐binding protein of an ABC transporter, by base pairing with the 5′ untranslated region of *BP3831* mRNA.[^11^](#mim12791-bib-0011){ref-type="ref"}, [^14^](#mim12791-bib-0014){ref-type="ref"} Although this protein is related to the transport of glutamate, it currently remains unclear whether RgtA is involved in the pathogenesis of *B. pertussis*. In the present study, we identified nine types of novel sRNAs that were strongly expressed during the bacterial colonization, and demonstrated that the expression of four types of sRNAs (Bpr4, 5, 8, and 9) was stronger *in vivo* than *in vitro*. To the best of our knowledge, this is the first study to identify the *in vivo* strongly expressed sRNAs of *B. pertussis*. Bpr4, 5, 8, and 9, which were strongly expressed *in vivo*, may be involved in regulating the expression of genes necessary for the bacterial colonization or infection. In *Salmonella enterica* serovar Typhimurium, PinT, a PhoP‐induced sRNA, was shown to be upregulated by up to 100‐fold during the infection, and regulated the expression of the invasion‐associated effectors and virulence genes required for intracellular survival.[^17^](#mim12791-bib-0017){ref-type="ref"} Li *et al*. also reported that Ysr170, a strongly expressed sRNA in *Yersinia pestis* invading host cells, contributed to the bacterial intracellular survival.[^18^](#mim12791-bib-0018){ref-type="ref"} These findings support our hypothesis that the sRNAs strongly induced during infection are involved in the adaptation and/or pathogenesis of *B. pertussis*. In addition, we found that the expression of Bpr1--7 and 9 was not regulated by the BvgAS system. Although the BvgAS system was previously considered to be the master virulence regulator in *B. pertussis*,[^3^](#mim12791-bib-0003){ref-type="ref"} recent studies demonstrated that the expression profiles of Bvg‐regulated genes were largely different between *in vitro* and *in vivo* conditions,[^4^](#mim12791-bib-0004){ref-type="ref"}, [^5^](#mim12791-bib-0005){ref-type="ref"} suggesting a complex mechanism that regulates *in vivo* gene expression. Several groups reported the PlrSR two‐component system and BspR/BtrA, an anti‐σ factor, as accessory regulatory systems downstream of BvgAS, which may play a part in this complex gene regulatory system *in vivo*.[^24^](#mim12791-bib-0024){ref-type="ref"}, [^25^](#mim12791-bib-0025){ref-type="ref"}, [^26^](#mim12791-bib-0026){ref-type="ref"}, [^27^](#mim12791-bib-0027){ref-type="ref"} Besides these regulators, the sRNAs identified in the present study may function as another regulator for gene expression during *B. pertussis* infection. Further research is currently in progress in our laboratory to identify genes whose expression is regulated by the sRNAs and elucidate the mechanisms by which the sRNAs regulate the gene expression.
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